GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4Results posted

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

152

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c ≥6.5%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05706506

Org study ID18520

Secondary ID2022-002708-18

Secondary IDI8F-MC-GPILEli Lilly and Company

Timeline

Milestones

Study first posted2023-01-31actual

Study start2023-03-08actual

Primary completion2023-10-31actual

Study completion2023-10-31actual

Last update posted2024-12-13actual

Results first posted2024-12-13actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have Type 2 diabetes (T2D)

•Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)

•Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening

•Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months

•No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.

Exclusion criteria

•Have Type 1 Diabetes (T1D)

•Have a clinical history of

–proliferative diabetic retinopathy

–diabetic maculopathy, or

–non-proliferative diabetic retinopathy that requires acute treatment

•Are at high risk for cardiovascular disease or have a history of

–myocardial infarction

–percutaneous coronary revascularization procedure

–carotid stenting or surgical revascularization

–nontraumatic amputation

–peripheral vascular procedure

–cerebrovascular accident

–or hospitalization for congestive heart failure

•Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure

•Have a history of ketoacidosis or hyperosmolar state or coma

•Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

2 endpoints

Secondary/registry result

Change From Baseline in Weight

Time frame:Baseline, Week 12

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
5 mg Tirzepatide	-2.15	—

Secondary/protocol endpoint

Change From Baseline in Weight

Time frame:Baseline, Week 12

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Primary/registry result

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 12

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), Percentage of HbA1c	95% CI
5 mg Tirzepatide	-0.43	—

Primary/protocol endpoint

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 12

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))

Time frame:Baseline, Week 4

CGM time-above-range

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Percentage of time per day	95% CI
5 mg Tirzepatide	-6.52	—

Secondary/registry result

Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 12

CGM time-above-range

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Percentage of time per day	95% CI
5 mg Tirzepatide	-7.37	—

Secondary/registry result

Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 4

CGM time-above-range

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Minutes per day	95% CI
5 mg Tirzepatide	-93.82	—

Secondary/registry result

Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 12

CGM time-above-range

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Minutes per day	95% CI
5 mg Tirzepatide	-106.09	—

Secondary/registry result

Change From Baseline in Fasting Serum Glucose (FSG)

Time frame:Baseline, Week 12

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
5 mg Tirzepatide	-7.83	—

Secondary/protocol endpoint

Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))

Time frame:Baseline, Week 4

CGM time-above-range

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 12

CGM time-above-range

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 4

CGM time-above-range

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Time frame:Baseline, Week 12

CGM time-above-range

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Fasting Serum Glucose (FSG)

Time frame:Baseline, Week 12

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.